RxDoctor Payments Data

Michael Gilbert, MD

Ophthalmology · Bellevue, WANPI 1386646065

Payments from drug & device makers

$4,435in general payments, 2019–2025

Across 77 payments — averaging $57.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$2K
  • Alcon$691
  • Glaukos Corporation$413
  • Rxsight Inc$165
  • Ivantis, Inc$163
  • Bausch & Lomb Americas Inc.$146
  • plus $583 from 10 others

What the payments were for

  • Travel & lodging$3718%
  • Food & beverage$4,06492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,435 in reported general payments places this provider in the 80th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$371,730
Medicare patients
856
Services billed
2,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost239$100,590
XiidraLifitegrast61$59,748
VyzultaLatanoprostene Bunod127$56,178
RestasisCyclosporine49$38,273
RhopressaNetarsudil Mesylate75$32,524
ProlensaBromfenac Sodium73$25,183
Loteprednol Etabonate158$20,608
TyrvayaVarenicline Tartrate21$13,296
SimbrinzaBrinzolamide/Brimonidine Tart22$10,120
Prednisolone Acetate235$9,466
LumiganBimatoprost25$8,468
Bromfenac Sodium36$8,068
Travoprost73$7,881
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat398$5,595
Lotemax SmLoteprednol Etabonate12$3,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$146$115,926188 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax Sm$144$48,821243 claims
AbbVieRestasis, Lumigan$70$46,74174 claims
Oyster Point Pharma, Inc.Tyrvaya$36$13,29621 claims
AlconSimbrinza$691$10,12022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →